nuclear-medicine-radiation-therapy-2018-tracks

Page 40

Journal of Medical Physics and Applied Sciences

ISSN: 2574-285X

I n t e r n a t i o n a l C o n f e r e n c e o n

Nuclear Medicine &

Radiation Therapy

Nuclear Medicine & Radiation Therapy 2018

O c t o b e r 0 1 - 0 2 , 2 0 1 8

S t o c k h o l m , S w e d e n

Current Trends in PET Radiopharmacy, Diagnostic &

Therapeutic Applications

Tamer B. Bayomy, PhD, ABSNM

Nuclear Medicine Department, International Medical Centre, Cairo, Egypt

Biography

Dr. Tamer has completed his PhD at the age of 33 years from

Cairo University. He is an Expert / Lecturer for the IAEA since

2010. He was granted the American Board in Radiopharma-

cy in June 2014. He is the head of the Cyclotron Department,

International Medical Centre, Cairo, Egypt from 2016 till now.

He worked as the Head of Cyclotron in King Hamad University

Hospital, Bahrain from 2012 to 2016. Worked as Senior Radio-

pharmacist and acting cyclotron head in King Fahd Specialist

Hospital, Dammam, Saudi Arabia from 2005 to 2012.

ET radiopharmaceuticals are extensively used all over the world for different

diagnostic and therapeuticapplications. Although

F-FDG is themost common

tracer being used in PET diagnosis, many other cyclotron and generator produced

radiopharmaceuticals are dragging more attention to cover the known limitations

of FDG. Theranostics are trending now as a successful combination of a predictive

biomarker with a therapeutic agent that showing confident achievements in

specific targeted therapy.

Tamer B. Bayomy, J. med phys & appl sci 2018, Volume: 3

DOI: 10.21767/2574-285X-C1-002